VIGL
vs
S&P 500
VIGL
S&P 500
Over the past 12 months, VIGL has significantly outperformed S&P 500, delivering a return of +201% compared to the S&P 500's +16% growth.
Stocks Performance
VIGL vs S&P 500
Performance Gap
VIGL vs S&P 500
Performance By Year
VIGL vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Vigil Neuroscience Inc
Glance View
Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. The company is headquartered in Cambridge, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2022-01-07. The firm is a microglia-focused therapeutics company. The company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. The company utilizes the tools of modern neuroscience drug development across multiple therapeutic modalities to deliver precision-based therapies to improve the lives of patients and their families. The firm's VGL101, a fully human monoclonal antibody targeting human TREM2 for the treatment of rare microgliopathies. The company is developing VGL101 for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare, genetically defined, and fatal neurodegenerative disease caused by microglial dysfunction. The firm is also developing a novel small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction.
